PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Sarepta Therapeutics, Inc. (SRPT)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US8036071004

CUSIP

803607100

Sector

Healthcare

IPO Date

Jun 3, 1997

Highlights

Market Cap

$10.18B

EPS (TTM)

$1.54

PE Ratio

69.23

PEG Ratio

159.25

Total Revenue (TTM)

$1.64B

Gross Profit (TTM)

$1.40B

EBITDA (TTM)

$153.37M

Year Range

$78.67 - $173.25

Target Price

$189.86

Short %

6.13%

Short Ratio

7.15

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
SRPT vs. WULF SRPT vs. NTRA SRPT vs. COST SRPT vs. ASM SRPT vs. INSM SRPT vs. DAVE SRPT vs. ML SRPT vs. SPY SRPT vs. CLS SRPT vs. ANF
Popular comparisons:
SRPT vs. WULF SRPT vs. NTRA SRPT vs. COST SRPT vs. ASM SRPT vs. INSM SRPT vs. DAVE SRPT vs. ML SRPT vs. SPY SRPT vs. CLS SRPT vs. ANF

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Sarepta Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-20.00%-10.00%0.00%10.00%20.00%30.00%JuneJulyAugustSeptemberOctoberNovember
-13.59%
11.50%
SRPT (Sarepta Therapeutics, Inc.)
Benchmark (^GSPC)

Returns By Period

Sarepta Therapeutics, Inc. had a return of 14.96% year-to-date (YTD) and 31.85% in the last 12 months. Over the past 10 years, Sarepta Therapeutics, Inc. had an annualized return of 21.62%, outperforming the S&P 500 benchmark which had an annualized return of 11.13%.


SRPT

YTD

14.96%

1M

-12.92%

6M

-13.59%

1Y

31.85%

5Y (annualized)

0.71%

10Y (annualized)

21.62%

^GSPC (Benchmark)

YTD

24.05%

1M

1.08%

6M

11.50%

1Y

30.38%

5Y (annualized)

13.77%

10Y (annualized)

11.13%

Monthly Returns

The table below presents the monthly returns of SRPT, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202423.40%7.49%1.22%-2.16%2.53%21.67%-9.97%-4.54%-8.02%0.89%14.96%
2023-3.56%-2.27%12.86%-10.93%0.68%-7.35%-5.35%11.64%0.17%-44.47%20.75%18.64%-25.58%
2022-20.52%7.04%1.97%-7.42%0.69%2.94%24.00%17.68%1.06%3.15%7.71%5.51%43.90%
2021-47.56%-2.62%-14.39%-4.95%6.79%2.76%-12.81%15.26%18.38%-14.44%2.12%11.43%-47.18%
2020-10.14%-1.28%-14.55%20.51%29.17%5.30%-4.25%-4.62%-4.09%-3.22%3.64%21.04%32.12%
201928.02%3.24%-17.37%-1.89%-2.64%33.47%-2.04%-39.44%-16.45%10.28%35.43%14.71%18.24%
201817.79%-4.23%18.03%3.06%22.90%40.84%-12.06%18.75%17.00%-17.18%-3.21%-15.71%96.14%
201713.23%0.16%-4.85%22.50%-17.71%12.97%14.45%4.43%12.58%8.71%12.90%-0.05%102.84%
2016-69.21%15.40%42.38%-27.31%47.50%-8.89%32.56%3.12%135.56%-36.10%-12.69%-19.94%-28.90%
2015-17.07%15.83%-4.46%-8.13%110.00%18.77%4.90%11.84%-10.06%-25.07%52.78%4.95%166.62%
201419.69%19.07%-17.22%54.52%-9.29%-11.55%-28.37%7.45%-7.98%-23.36%4.76%-14.58%-28.96%
20134.84%8.30%26.13%-21.41%21.73%7.61%-2.78%-7.71%38.38%-17.61%-52.10%9.28%-21.05%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of SRPT is 66, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.


The Risk-Adjusted Performance Rank of SRPT is 6666
Combined Rank
The Sharpe Ratio Rank of SRPT is 6565
Sharpe Ratio Rank
The Sortino Ratio Rank of SRPT is 7070
Sortino Ratio Rank
The Omega Ratio Rank of SRPT is 6666
Omega Ratio Rank
The Calmar Ratio Rank of SRPT is 6767
Calmar Ratio Rank
The Martin Ratio Rank of SRPT is 6464
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Sarepta Therapeutics, Inc. (SRPT) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for SRPT, currently valued at 0.68, compared to the broader market-4.00-2.000.002.004.000.682.46
The chart of Sortino ratio for SRPT, currently valued at 1.62, compared to the broader market-4.00-2.000.002.004.001.623.31
The chart of Omega ratio for SRPT, currently valued at 1.20, compared to the broader market0.501.001.502.001.201.46
The chart of Calmar ratio for SRPT, currently valued at 0.61, compared to the broader market0.002.004.006.000.613.55
The chart of Martin ratio for SRPT, currently valued at 2.26, compared to the broader market-10.000.0010.0020.0030.002.2615.76
SRPT
^GSPC

The current Sarepta Therapeutics, Inc. Sharpe ratio is 0.68. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Sarepta Therapeutics, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.

Rolling 12-month Sharpe Ratio0.001.002.003.00JuneJulyAugustSeptemberOctoberNovember
0.68
2.46
SRPT (Sarepta Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Sarepta Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-40.00%-30.00%-20.00%-10.00%0.00%JuneJulyAugustSeptemberOctoberNovember
-37.98%
-1.40%
SRPT (Sarepta Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Sarepta Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Sarepta Therapeutics, Inc. was 98.17%, occurring on Dec 18, 2008. Recovery took 2458 trading sessions.

The current Sarepta Therapeutics, Inc. drawdown is 37.98%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.17%Feb 10, 20002228Dec 18, 20082458Sep 26, 20184686
-73.03%Oct 8, 1997358Mar 11, 1999216Jan 18, 2000574
-64.93%Dec 23, 2020373Jun 16, 2022
-54.92%Oct 1, 2018249Sep 26, 2019182Jun 17, 2020431
-27.14%Jul 21, 202079Nov 9, 202028Dec 18, 2020107

Volatility

Volatility Chart

The current Sarepta Therapeutics, Inc. volatility is 11.16%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%JuneJulyAugustSeptemberOctoberNovember
11.16%
4.07%
SRPT (Sarepta Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Sarepta Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an assessment of the market value of Sarepta Therapeutics, Inc. compared to its peers in the Biotechnology industry.


PE Ratio
200.0400.0600.069.2
The chart displays the price to earnings (P/E) ratio for SRPT in comparison to other companies of the Biotechnology industry. Currently, SRPT has a PE value of 69.2. This PE ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.
PEG Ratio
-1,000.0-800.0-600.0-400.0-200.00.0159.3
The chart displays the price to earnings to growth (PEG) ratio for SRPT in comparison to other companies of the Biotechnology industry. Currently, SRPT has a PEG value of 159.3. This PEG ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Sarepta Therapeutics, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items